Welcome!

I’m Peter, a software engineer with a background in molecular biology.

I write about choroideremia (an eye disease I have) and tech on this blog.

boon·dog·gle | / ˈbo͞onˌdäɡəl / (noun) – work or activity that is wasteful or pointless but gives the appearance of having value. This blog isn’t pointless, I just like puns.

Building some-recipes.com

Background Earlier this year I made my way through Fullstack Open, a course designed to teach modern Javascript-based web development. In their words: The main focus is on building single page applications with ReactJS that use REST APIs built with Node.js. The course also contains a section on GraphQL, a modern alternative to REST APIs. The course covers testing, configuration and environment management, and the use of MongoDB for storing the application’s data....

November 16, 2020 · 6 min · Peter Boone

How do Spotify Codes work?

Spotify Codes are QR-like codes that can be generated to easily share Spotify songs, artists, playlists, and users. I set out to figure out how they worked, which led me on a winding journey through barcode history, patents, packet sniffing, error correction, and Gray tables. Spotify URIs Let’s start with Spotify URIs (Uniform Resource Identifiers). Different pieces of media (artists, albums, songs, playlists, users) all have a URI. The ABBA song “Take a Chance on Me” has this URI:...

November 13, 2020 · 10 min · Peter Boone

Low mRNA levels in CHM patients

The article: Association of Messenger RNA Level With Phenotype in Patients With Choroideremia: Potential Implications for Gene Therapy Dose Background The central dogma of biology is simply that DNA makes RNA makes protein. Messenger RNA (mRNA) transfers the information from DNA and is used to create protein. The question this study ultimately seeks to answer is “How much mRNA is needed to have healthy retinal function in CHM patients?” It is important to know this information when conducting gene therapy clinical trials so an effective “dose” can be delivered....

February 23, 2020 · 2 min · Peter Boone

ASGCT Policy Summit, Day 3

Washington, DC - Nov. 6, 2019 The American Society of Gene and Cell Therapy held a 3 day summit to discuss policy and other issues around gene editing and gene therapy. Day 1 addressed regulatory issues in gene therapy development Day 2 dealt with payment policies around gene therapy Day 3 (the day I attended) was focused on the ethical, societal, and policy issues around germline gene editing Links to some of the presentations can be found on ASGCT’s website....

November 16, 2019 · 4 min · Peter Boone

ARVO 2019 Thursday Notes

Panorama view from Whistler Mountain. These notes from Thursday May 2, the last day of ARVO 2019. The conference had thinned out a bit as some people had to leave, but there were still some presentations of interest. You can read a summary or my notes from the other days here: Friday, Sunday, Monday, Tuesday, and Wednesday. Papers Subfoveal gene augmentation therapy for choroideremia: One-year results from a Phase I/II trial of AAV2-hCHM - Rachel M....

May 18, 2019 · 3 min · Peter Boone

ARVO 2019 Thursday Notes

Panorama view from Whistler Mountain. These notes from Thursday May 2, the last day of ARVO 2019. The conference had thinned out a bit as some people had to leave, but there were still some presentations of interest. You can read a summary or my notes from the other days here: Friday, Sunday, Monday, Tuesday, and Wednesday. Papers Subfoveal gene augmentation therapy for choroideremia: One-year results from a Phase I/II trial of AAV2-hCHM - Rachel M....

May 18, 2019 · 3 min · Peter Boone

ARVO 2019 Wednesday Notes

“Digital Orca” sculpture outside of the Vancouver Convention Center. These notes from May 1 are the continuation of a few articles about my time at ARVO. You can read a summary or my notes from the other days here: Friday, Sunday, Monday, Tuesday. Papers AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: 2 year Results of an Ongoing Phase I/II Gene Therapy Trial - Thomas Aleman Aleman presented more follow-up data from this phase I/II clinical trial that was performed on 10 CHM patients....

May 18, 2019 · 6 min · Peter Boone

ARVO 2019 Summary

ARVO 2019 took place at the Vancouver Convention Center from April 28 to May 2 and featured novel work, continued efforts, and updates on clinical trials. On the Friday before ARVO the Foundation Fighting Blindness and the Casey Eye Institute hosted a summit featuring gene therapy, stem cell therapies, and non-viral therapies. Randy Wheelock had been organizing a special interest group on Sunday to discuss combination therapies before his passing. Ian MacDonald and Chris Moen took over the organization of that event, which ended up being an honest discussion of the biggest obstacles researchers see ahead of them....

May 12, 2019 · 3 min · Peter Boone